Dry Eye Disease Market Report 2025-2034
Description
The dry eye disease market was valued at USD 6.94 Billion in 2024 driven by the development of innovative treatment options across the 8 major markets. It is expected to grow at a CAGR of 6.50% during the forecast period of 2025-2034 and attain a market value of USD 13.03 Billion by 2034. The market is driven by factors like aging populations, environmental influences (e.g., air pollution and screen time), and advances in diagnostic technologies and treatments, driving demand for effective management solutions.
Dry Eye Disease Market Overview
Dry eye disease is a common condition where the eyes do not produce enough tears or produce poor-quality tears, leading to irritation, redness, and a gritty sensation. It can result from aging, environmental factors, screen overuse, or underlying health issues. Symptoms often worsen in dry or windy conditions. If left untreated, it can affect vision and quality of life, but it is manageable with appropriate care and treatments. The market is expected to grow at a CAGR of 6.50% during the forecast period of 2025-2034.
Dry Eye Disease Market Growth Drivers
AI Integration and Clinical Study Partnerships to Boost Market Growth
The rising demand for AI integration in ophthalmology and the increasing focus on improving clinical data workflows are driving advancements in the dry eye disease (DED) market. For instance, in September 2024, RetinAI U.S. Inc. partnered with MAXO, a reading centre affiliated with TFS HealthScience, to support two critical DED clinical trials. These studies will utilize the AI-powered RetinAI Discovery® platform to optimize imaging analysis, real-time data sharing, and global collaboration. This development is expected to accelerate clinical research efficiency and fuel market growth during the forecast period.
Patient-Centric Research Enhancing Awareness and Dry Eye Disease Market Development
The growing focus on patient-centred care and quality-of-life evaluations in eye health are crucial market drivers. For instance, in February 2025, a study by Italian researchers used a narrative medicine approach to explore patient and caregiver experiences in dry eye disease. Involving 171 patients, 37 caregivers, and 81 ophthalmologists, the research offered qualitative insights into DED severity and emotional impact. This approach is anticipated to enhance understanding of patient needs, guide therapeutic strategies, and encourage innovation, thereby supporting dry eye disease market development in the coming years.
Dry Eye Disease Market Growth Trends
Some of the notable trends include rising product launches, adoption of novel delivery technologies, and changes in the regulatory support.
New Product Launches to Drive Dry Eye Disease Market Growth
In February 2025, Alcon launched SYSTANE PRO Preservative-Free in the United States. It is a triple-action OTC eye drop for dry eye relief. With 45.5 million Americans affected, the product’s innovative, preservative-free formulation and long-lasting hydration are expected to gain traction. This trend of advanced OTC product launches significantly boosts patient adoption, supporting market growth by expanding therapeutic options and improving patient outcomes for mild-to-moderate dry eye conditions.
Rising Approvals to Meet Dry Eye Disease Market Demand
In October 2024, Novaliq and Laboratoires Théa secured European Commission approval for Vevizye®, the only water-free ciclosporin 0.1% solution, for moderate to severe dry eye disease. This milestone reflects growing European investment in advanced formulations. Such regional regulatory successes not only bolster European market expansion but also foster global awareness and confidence in novel therapeutic platforms like EyeSol®, encouraging further innovation and market penetration.
Rise in Partnerships Between Leading Companies to Drive Dry Eye Disease Market Value
In July 2024, Eyenovia partnered with SGN Nanopharma to co-develop a micellar nanoparticle-based cyclosporine therapy delivered via the Optejet® device. With a largely diabetic population base, innovation in drug-device combinations aims to improve treatment precision and efficacy. These novel platforms are poised to increase the value proposition of cyclosporine-based therapies and redefine delivery standards in the dry eye disease market.
Dry Eye Disease Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Eye Drops and Solutions to Lead the Market Share by Dosage Form
Eye drops and solutions dominate the dry eye disease market due to their immediate relief, easy administration, and widespread availability. These formulations effectively hydrate and lubricate the eyes, making them the preferred choice for both over-the-counter and prescription use. Their ability to address various severity levels of dry eye symptoms positions them as the leading dosage form, driving market growth during the forecast period.
Dry Eye Disease Market Analysis by Region
The United States is poised to lead the market due to high disease prevalence, a growing aging population, and robust healthcare infrastructure. Increasing awareness, frequent screen exposure, and strong adoption of advanced therapies further support market dominance. Additionally, the presence of leading pharmaceutical players and substantial investments in R&D continue to drive innovation and fuel regional market growth throughout the forecast period.
Leading Players in the Dry Eye Disease Market
The key features of the market report comprise epidemiology, clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Novartis AG
Novartis is a key player in the dry eye In June 2022, Novartis AG acquired Kedalion Therapeutics and its AcuStream technology, a preservative-free, electromechanical ocular delivery platform enabling precise dosing of ophthalmic drugs. This strategic move enhances Novartis’s capabilities in dry eye disease treatment by improving drug delivery efficiency, positioning the company as a key innovator in ophthalmic care and contributing to the market’s technological advancement and growth.
AbbVie, Inc.
AbbVie, In., is a global healthcare company with a significant presence in the market. In April 2025, AbbVie submitted a Biologics License Application to the FDA for trenibotulinumtoxinE (TrenibotE), aiming to expand its aesthetics portfolio. While primarily for glabellar lines, AbbVie’s growing biologics expertise and robust regulatory progress also reinforce its ophthalmic R&D focus, potentially benefitting adjacent segments like dry eye disease and supporting the company’s role in the broader eyecare market.
Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd. specializes in products and services for ophthalmology care. In November 2024, Sun Pharmaceutical Industries Ltd. presented compelling Phase 4 data at ESCRS 2024 showing cyclosporine ophthalmic solution 0.09% (Cequa) significantly improved dry eye disease symptoms over 12 weeks in patients unresponsive to Restasis. This reinforces Sun Pharma’s leadership in DED therapy and highlights the potential for improved treatment outcomes, bolstering market confidence and therapeutic innovation.
Santen Pharmaceutical Co Ltd.
Santen Pharmaceutical is a global leader, offering a broad portfolio of products across multiple therapeutic areas. In July 2023, Harrow announced agreements with affiliates of Santen Pharmaceutical Co., Ltd. to acquire U.S. and Canadian commercial rights to select branded eyecare products. This move strengthens Santen’s strategic collaborations and market positioning while enhancing Harrow’s portfolio in dry eye and related indications, ultimately supporting regional market expansion and accessibility in North America.
Other key players in the market include AFT Pharmaceuticals, Johnson & Johnson, Otsuka Pharmaceutical (subsidiary of Otsuka Holdings Co., Ltd.), OASIS Medical, Viatris Inc, and Bausch Health Companies, Inc., among others.
Key Questions Answered in the Dry Eye Disease Market
Dry Eye Disease Market Overview
Dry eye disease is a common condition where the eyes do not produce enough tears or produce poor-quality tears, leading to irritation, redness, and a gritty sensation. It can result from aging, environmental factors, screen overuse, or underlying health issues. Symptoms often worsen in dry or windy conditions. If left untreated, it can affect vision and quality of life, but it is manageable with appropriate care and treatments. The market is expected to grow at a CAGR of 6.50% during the forecast period of 2025-2034.
Dry Eye Disease Market Growth Drivers
AI Integration and Clinical Study Partnerships to Boost Market Growth
The rising demand for AI integration in ophthalmology and the increasing focus on improving clinical data workflows are driving advancements in the dry eye disease (DED) market. For instance, in September 2024, RetinAI U.S. Inc. partnered with MAXO, a reading centre affiliated with TFS HealthScience, to support two critical DED clinical trials. These studies will utilize the AI-powered RetinAI Discovery® platform to optimize imaging analysis, real-time data sharing, and global collaboration. This development is expected to accelerate clinical research efficiency and fuel market growth during the forecast period.
Patient-Centric Research Enhancing Awareness and Dry Eye Disease Market Development
The growing focus on patient-centred care and quality-of-life evaluations in eye health are crucial market drivers. For instance, in February 2025, a study by Italian researchers used a narrative medicine approach to explore patient and caregiver experiences in dry eye disease. Involving 171 patients, 37 caregivers, and 81 ophthalmologists, the research offered qualitative insights into DED severity and emotional impact. This approach is anticipated to enhance understanding of patient needs, guide therapeutic strategies, and encourage innovation, thereby supporting dry eye disease market development in the coming years.
Dry Eye Disease Market Growth Trends
Some of the notable trends include rising product launches, adoption of novel delivery technologies, and changes in the regulatory support.
New Product Launches to Drive Dry Eye Disease Market Growth
In February 2025, Alcon launched SYSTANE PRO Preservative-Free in the United States. It is a triple-action OTC eye drop for dry eye relief. With 45.5 million Americans affected, the product’s innovative, preservative-free formulation and long-lasting hydration are expected to gain traction. This trend of advanced OTC product launches significantly boosts patient adoption, supporting market growth by expanding therapeutic options and improving patient outcomes for mild-to-moderate dry eye conditions.
Rising Approvals to Meet Dry Eye Disease Market Demand
In October 2024, Novaliq and Laboratoires Théa secured European Commission approval for Vevizye®, the only water-free ciclosporin 0.1% solution, for moderate to severe dry eye disease. This milestone reflects growing European investment in advanced formulations. Such regional regulatory successes not only bolster European market expansion but also foster global awareness and confidence in novel therapeutic platforms like EyeSol®, encouraging further innovation and market penetration.
Rise in Partnerships Between Leading Companies to Drive Dry Eye Disease Market Value
In July 2024, Eyenovia partnered with SGN Nanopharma to co-develop a micellar nanoparticle-based cyclosporine therapy delivered via the Optejet® device. With a largely diabetic population base, innovation in drug-device combinations aims to improve treatment precision and efficacy. These novel platforms are poised to increase the value proposition of cyclosporine-based therapies and redefine delivery standards in the dry eye disease market.
Dry Eye Disease Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Evaporative Dry Eye Syndrome
- Aqueous Deficient Dry Eye Syndrome
- Anti-inflammatory Products
- Cyclosporine
- Corticosteroids
- Artificial Tears and Lubricants
- Others
- Eye Drops/Solutions
- Ointments and Gels
- Capsules and Tablets
- Over the Counter (OTC)
- Prescription
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Eye Drops and Solutions to Lead the Market Share by Dosage Form
Eye drops and solutions dominate the dry eye disease market due to their immediate relief, easy administration, and widespread availability. These formulations effectively hydrate and lubricate the eyes, making them the preferred choice for both over-the-counter and prescription use. Their ability to address various severity levels of dry eye symptoms positions them as the leading dosage form, driving market growth during the forecast period.
Dry Eye Disease Market Analysis by Region
The United States is poised to lead the market due to high disease prevalence, a growing aging population, and robust healthcare infrastructure. Increasing awareness, frequent screen exposure, and strong adoption of advanced therapies further support market dominance. Additionally, the presence of leading pharmaceutical players and substantial investments in R&D continue to drive innovation and fuel regional market growth throughout the forecast period.
Leading Players in the Dry Eye Disease Market
The key features of the market report comprise epidemiology, clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Novartis AG
Novartis is a key player in the dry eye In June 2022, Novartis AG acquired Kedalion Therapeutics and its AcuStream technology, a preservative-free, electromechanical ocular delivery platform enabling precise dosing of ophthalmic drugs. This strategic move enhances Novartis’s capabilities in dry eye disease treatment by improving drug delivery efficiency, positioning the company as a key innovator in ophthalmic care and contributing to the market’s technological advancement and growth.
AbbVie, Inc.
AbbVie, In., is a global healthcare company with a significant presence in the market. In April 2025, AbbVie submitted a Biologics License Application to the FDA for trenibotulinumtoxinE (TrenibotE), aiming to expand its aesthetics portfolio. While primarily for glabellar lines, AbbVie’s growing biologics expertise and robust regulatory progress also reinforce its ophthalmic R&D focus, potentially benefitting adjacent segments like dry eye disease and supporting the company’s role in the broader eyecare market.
Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd. specializes in products and services for ophthalmology care. In November 2024, Sun Pharmaceutical Industries Ltd. presented compelling Phase 4 data at ESCRS 2024 showing cyclosporine ophthalmic solution 0.09% (Cequa) significantly improved dry eye disease symptoms over 12 weeks in patients unresponsive to Restasis. This reinforces Sun Pharma’s leadership in DED therapy and highlights the potential for improved treatment outcomes, bolstering market confidence and therapeutic innovation.
Santen Pharmaceutical Co Ltd.
Santen Pharmaceutical is a global leader, offering a broad portfolio of products across multiple therapeutic areas. In July 2023, Harrow announced agreements with affiliates of Santen Pharmaceutical Co., Ltd. to acquire U.S. and Canadian commercial rights to select branded eyecare products. This move strengthens Santen’s strategic collaborations and market positioning while enhancing Harrow’s portfolio in dry eye and related indications, ultimately supporting regional market expansion and accessibility in North America.
Other key players in the market include AFT Pharmaceuticals, Johnson & Johnson, Otsuka Pharmaceutical (subsidiary of Otsuka Holdings Co., Ltd.), OASIS Medical, Viatris Inc, and Bausch Health Companies, Inc., among others.
Key Questions Answered in the Dry Eye Disease Market
- What was the dry eye disease market value in 2024?
- What is the dry eye disease market forecast outlook for 2025-2034?
- What are the major factors aiding the dry eye disease market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major dry eye disease market trends?
- Which type will lead the market segment?
- Which drug class will lead the market segment?
- Which dosage form will lead the market segment?
- Which sales channel will lead the market segment?
- Which end user will lead the market segment?
- Which distribution channel will lead the market segment?
- Who are the key players involved in the dry eye disease market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Dry Eye Disease Market Overview – 8 Major Markets
- 3.1 Dry Eye Disease Market Historical Value (2018-2024)
- 3.2 Dry Eye Disease Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Dry Eye Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Dry Eye Disease Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence of Dry Eye Disease, By Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 Germany
- 7.2.4 France
- 7.2.5 Italy
- 7.2.6 Spain
- 7.2.7 India
- 7.2.8 Japan
- 7.3 Total Diagnosed Cases of Dry Eye Disease, By Country
- 7.4 Gender-specific Prevalence of Dry Eye Disease, By Country
- 7.5 Age-specific Prevalence of Dry Eye Disease, By Country
- 7.6 Treatment Seeking Rate of Dry Eye Disease, By Country
- 8 Dry Eye Disease Market Landscape – 8 Major Markets
- 8.1 Dry Eye Disease Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Dry Eye Disease Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Drug Class
- 8.2.3 Analysis by Dosage Form
- 8.2.4 Analysis by Sales Channel
- 9 Clinical Trials and Pipeline Analysis
- 9.1 Analysis by Trial Registration Year
- 9.2 Analysis by Trial Status
- 9.3 Analysis by Trial Phase
- 9.4 Analysis by Therapeutic Area
- 9.5 Analysis by Geography
- 9.6 Drug Pipeline Assessment
- 10 Dry Eye Disease Market Challenges and Unmet Needs
- 10.1 Treatment Pathway Challenges
- 10.2 Compliance and Drop-Out Analysis
- 10.3 Awareness and Prevention Gaps
- 11 Cost of Treatment
- 12 Dry Eye Disease Market Dynamics
- 12.1 Market Drivers and Constraints
- 12.2 SWOT Analysis
- 12.2.1 Strengths
- 12.2.2 Weaknesses
- 12.2.3 Opportunities
- 12.2.4 Threats
- 12.3 PESTEL Analysis
- 12.3.1 Political
- 12.3.2 Economic
- 12.3.3 Social
- 12.3.4 Technological
- 12.3.5 Legal
- 12.3.6 Environment
- 12.4 Porter’s Five Forces Model
- 12.4.1 Bargaining Power of Suppliers
- 12.4.2 Bargaining Power of Buyers
- 12.4.3 Threat of New Entrants
- 12.4.4 Threat of Substitutes
- 12.4.5 Degree of Rivalry
- 12.5 Key Demand Indicators
- 12.6 Key Price Indicators
- 12.7 Industry Events, Initiatives, and Trends
- 12.8 Value Chain Analysis
- 13 Dry Eye Disease Market Segmentation (218-2034) - 8 Major Markets
- 13.1 Dry Eye Disease Market (2018-2034) by Type
- 13.1.1 Market Overview
- 13.1.2 Evaporative Dry Eye Syndrome
- 13.1.3 Aqueous Deficient Dry Eye Syndrome
- 13.2 Dry Eye Disease Market (2018-2034) by Drug Class
- 13.2.1 Market Overview
- 13.2.2 Anti-inflammatory Products
- 13.2.3 Cyclosporine
- 13.2.4 Corticosteroids
- 13.2.5 Artificial Tears and Lubricants
- 13.2.6 Others
- 13.3 Dry Eye Disease Market (2018-2034) by Dosage Form
- 13.3.1 Market Overview
- 13.3.2 Eye Drops/ Solutions
- 13.3.3 Ointments and Gels
- 13.3.4 Capsules & Tablets
- 13.4 Dry Eye Disease Market (2018-2034) by Sales Channel
- 13.4.1 Market Overview
- 13.4.2 Over the Counter (OTC)
- 13.4.3 Prescription
- 13.5 Dry Eye Disease Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Specialty Clinics
- 13.5.4 Homecare Settings
- 13.5.5 Others
- 13.6 Dry Eye Disease Market (2018-2034) by Distribution Channel
- 13.6.1 Market Overview
- 13.6.2 Hospital Pharmacies
- 13.6.3 Retail Pharmacies
- 13.6.4 Online Channels
- 13.7 Dry Eye Disease Market (2018-2034) by Region
- 13.7.1 Market Overview
- 13.7.2 United States
- 13.7.3 United Kingdom
- 13.7.4 Germany
- 13.7.5 France
- 13.7.6 Italy
- 13.7.7 Spain
- 13.7.8 Japan
- 13.7.9 India
- 14 United States Dry Eye Disease Market (218-2034)
- 14.1 United States Dry Eye Disease Market (2018-2034) by Type
- 14.1.1 Market Overview
- 14.1.2 Evaporative Dry Eye Syndrome
- 14.1.3 Aqueous Deficient Dry Eye Syndrome
- 14.2 United States Dry Eye Disease Market (2018-2034) by Drug Class
- 14.2.1 Market Overview
- 14.2.2 Anti-inflammatory Products
- 14.2.3 Cyclosporine
- 14.2.4 Corticosteroids
- 14.2.5 Artificial Tears and Lubricants
- 14.2.6 Others
- 14.3 United States Dry Eye Disease Market (2018-2034) by Dosage Form
- 14.3.1 Market Overview
- 14.3.2 Eye Drops/ Solutions
- 14.3.3 Ointments and Gels
- 14.3.4 Capsules & Tablets
- 14.3.5 Others
- 14.4 United States Dry Eye Disease Market (2018-2034) by Sales Channel
- 14.4.1 Market Overview
- 14.4.2 Over the Counter (OTC)
- 14.4.3 Prescription
- 14.5 United States Dry Eye Disease Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals
- 14.5.3 Specialty Clinics
- 14.5.4 Homecare Settings
- 14.5.5 Others
- 14.6 United States Dry Eye Disease Market (2018-2034) by Distribution Channel
- 14.6.1 Market Overview
- 14.6.2 Hospital Pharmacies
- 14.6.3 Retail Pharmacies
- 14.6.4 Online Channels
- 15 United Kingdom Dry Eye Disease Market (218-2034)
- 15.1 United Kingdom Dry Eye Disease Market (2018-2034) by Type
- 15.2 United Kingdom Dry Eye Disease Market (2018-2034) by Drug Class
- 15.3 United Kingdom Dry Eye Disease Market (2018-2034) by Dosage Form
- 15.4 United Kingdom Dry Eye Disease Market (2018-2034) by Sales Channel
- 15.5 United Kingdom Dry Eye Disease Market (2018-2034) by End User
- 15.6 United Kingdom Dry Eye Disease Market (2018-2034) by Distribution Channel
- 16 Germany Dry Eye Disease Market (218-2034)
- 16.1 Germany Dry Eye Disease Market (2018-2034) by Type
- 16.2 Germany Dry Eye Disease Market (2018-2034) by Drug Class
- 16.3 Germany Dry Eye Disease Market (2018-2034) by Dosage Form
- 16.4 Germany Dry Eye Disease Market (2018-2034) by Sales Channel
- 16.5 Germany Dry Eye Disease Market (2018-2034) by End User
- 16.6 Germany Dry Eye Disease Market (2018-2034) by Distribution Channel
- 17 France Dry Eye Disease Market (218-2034)
- 17.1 France Dry Eye Disease Market (2018-2034) by Type
- 17.2 France Dry Eye Disease Market (2018-2034) by Drug Class
- 17.3 France Dry Eye Disease Market (2018-2034) by Dosage Form
- 17.4 France Dry Eye Disease Market (2018-2034) by Sales Channel
- 17.5 France Dry Eye Disease Market (2018-2034) by End User
- 17.6 France Dry Eye Disease Market (2018-2034) by Distribution Channel
- 18 Italy Dry Eye Disease Market (218-2034)
- 18.1 Italy Dry Eye Disease Market (2018-2034) by Type
- 18.2 Italy Dry Eye Disease Market (2018-2034) by Drug Class
- 18.3 Italy Dry Eye Disease Market (2018-2034) by Dosage Form
- 18.4 Italy Dry Eye Disease Market (2018-2034) by Sales Channel
- 18.5 Italy Dry Eye Disease Market (2018-2034) by End User
- 18.6 Italy Dry Eye Disease Market (2018-2034) by Distribution Channel
- 19 Spain Dry Eye Disease Market (218-2034)
- 19.1 Spain Dry Eye Disease Market (2018-2034) by Type
- 19.2 Spain Dry Eye Disease Market (2018-2034) by Drug Class
- 19.3 Spain Dry Eye Disease Market (2018-2034) by Dosage Form
- 19.4 Spain Dry Eye Disease Market (2018-2034) by Sales Channel
- 19.5 Spain Dry Eye Disease Market (2018-2034) by End User
- 19.6 Spain Dry Eye Disease Market (2018-2034) by Distribution Channel
- 20 Japan Dry Eye Disease Market (218-2034)
- 20.1 Japan Dry Eye Disease Market (2018-2034) by Type
- 20.2 Japan Dry Eye Disease Market (2018-2034) by Drug Class
- 20.3 Japan Dry Eye Disease Market (2018-2034) by Dosage Form
- 20.4 Japan Dry Eye Disease Market (2018-2034) by Sales Channel
- 20.5 Japan Dry Eye Disease Market (2018-2034) by End User
- 20.6 Japan Dry Eye Disease Market (2018-2034) by Distribution Channel
- 21 India Dry Eye Disease Market (218-2034)
- 21.1 India Dry Eye Disease Market (2018-2034) by Type
- 21.2 India Dry Eye Disease Market (2018-2034) by Drug Class
- 21.3 India Dry Eye Disease Market (2018-2034) by Dosage Form
- 21.4 India Dry Eye Disease Market (2018-2034) by Sales Channel
- 21.5 India Dry Eye Disease Market (2018-2034) by End User
- 21.6 India Dry Eye Disease Market (2018-2034) by Distribution Channel
- 22 Regulatory Framework
- 22.1 Regulatory Overview
- 22.2 US FDA
- 22.3 EU EMA
- 22.4 Japan PMDA
- 22.5 India CDSCO
- 22.6 Others
- 23 Patent Analysis
- 23.1 Analysis by Technology
- 23.2 Analysis by Publication Year
- 23.3 Analysis by Issuing Authority
- 23.4 Analysis by Patent Age
- 23.5 Analysis by CPC Codes
- 23.6 Analysis by Patent Valuation
- 24 Grants Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Type of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Type of Partnership
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share Analysis, By Region (Top 5 Companies)
- 27.2 Novartis AG
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Company News and Developments
- 27.2.5 Certifications
- 27.3 AbbVie, Inc.
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Company News and Developments
- 27.3.5 Certifications
- 27.4 Sun Pharmaceutical Industries Ltd.
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Company News and Developments
- 27.4.5 Certifications
- 27.5 Santen Pharmaceutical Co Ltd.
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Company News and Developments
- 27.5.5 Certifications
- 27.6 AFT Pharmaceuticals
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Company News and Developments
- 27.6.5 Certifications
- 27.7 Johnson & Johnson Innovative Medicines
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Company News and Developments
- 27.7.5 Certifications
- 27.8 Otsuka Pharmaceutical Co., Ltd. (subsidiary of Otsuka Holdings Co., Ltd.)
- 27.8.1 Financial Analysis
- 27.8.2 Product Portfolio
- 27.8.3 Demographic Reach and Achievements
- 27.8.4 Company News and Developments
- 27.8.5 Certifications
- 27.9 OASIS Medical
- 27.9.1 Financial Analysis
- 27.9.2 Product Portfolio
- 27.9.3 Demographic Reach and Achievements
- 27.9.4 Company News and Developments
- 27.9.5 Certifications
- 27.10 Viatris Inc.
- 27.10.1 Financial Analysis
- 27.10.2 Product Portfolio
- 27.10.3 Demographic Reach and Achievements
- 27.10.4 Company News and Developments
- 27.10.5 Certifications
- 27.11 Bausch Health Companies, Inc.
- 27.11.1 Financial Analysis
- 27.11.2 Product Portfolio
- 27.11.3 Demographic Reach and Achievements
- 27.11.4 Company News and Developments
- 27.11.5 Certifications
- 28 Dry Eye Disease Market - Distribution Model (Additional Insight)
- 28.1 Overview
- 28.2 Potential Distributors
- 28.3 Key Parameters for Distribution Partner Assessment
- 29 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 30 Payment Methods (Additional Insight)
- 30.1 Government Funded
- 30.2 Private Insurance
- 30.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
